Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Zhaoke Ophthalmology (06622.HK) Expects Multiple Product Approvals in 2HYY; Aims to Expand International Network to Latin America or South America This Year
Recommend 3 Positive 2 Negative 2 |
||||
|
||||
|
Zhaoke Ophthalmology-B (06622.HK) Chairman, Executive Director, and CEO William Li expects that multiple product applications under the group will be approved in the second half of the year. Among them, Li stated that the National Medical Products Administration accepted the new drug application for cyclosporine ophthalmic gel last May, and the FDA approved the new drug trial application last June. Atropine sulfate eye drops (NVK002) are currently under regulatory review for market approval. The bevacizumab intravitreal injection (TAB014) for treating wet age-related macular degeneration has been submitted for a biologics license application in China and is expected to be approved within the year, potentially entering the National Medical Insurance Drug List. He also revealed that the group has established a legally compliant internet hospital in Nansha, Guangzhou, primarily for patient management. Regarding overseas markets, he noted that the group covered Southeast Asia, the Middle East, South Korea, and Europe last year. This year, they hope to expand their international network to Latin America or South America and are actively seeking opportunities in Brazil. He mentioned that based on the current development progress of Zhaoke's various drugs, including the strategic partner's FDA approval for the innovative presbyopia drug Brimochol PF earlier this year, Zhaoke's overseas business could start generating revenue as early as 2028. In the long term, Zhaoke aims for its overseas and domestic revenue to each account for half of the total. Regarding Zhaoke Ophthalmology's recent full-year results, the loss narrowed from RMB237 million in the previous year to RMB209 million. The group's Vice President of Finance and Company Secretary, Qiu Shuxin, expects that with more products being approved for market next year, the product portfolio will become more diversified. Coupled with the company's conservative administrative expenses, the loss is expected to gradually narrow. She mentioned that the company will cautiously invest in R&D expenses going forward. If the group's products can be launched on schedule, cash outflows are expected to significantly decrease. (sl/da) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. |
||||
Copied to Clipboard
 |
||||
